Kontafarma China Holdings Ltd. has announced its unaudited interim results for the six months ended June 30, 2025. The Group reported total revenue of HK$452.7 million, a slight decrease from HK$458.5 million in the same period of 2024. The pharmaceutical business segment recorded a revenue of HK$344.8 million, nearly stable compared to HK$345.4 million the previous year. However, the fitness business segment saw a decline in revenue, reporting HK$108.0 million compared to HK$113.1 million in 2024. The Group's overall segment results were a loss of HK$318.3 million, in contrast to a profit of HK$21.9 million in the previous year. The pharmaceutical business segment reported a profit of HK$20.4 million, down from HK$60.5 million in 2024, primarily due to a decrease in gross profit and increased marketing expenses to counteract market competition. Meanwhile, the fitness business recorded a significant loss of HK$338.7 million, compared to a loss of HK$38.5 million in 2024. The main factor affecting the revenue and profit decline was intensified market competition, which negatively impacted selling prices and gross profit. No specific outlook or guidance was provided for future periods.